ArticleNeuro-oncology2016

Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study.

Rishi R Lulla et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.